Symptomatic and neuroprotective effects following activation of nigral group III metabotropic glutamate receptors in rodent models of Parkinson's disease
about
Neuroprotective and symptomatic effects of targeting group III mGlu receptors in neurodegenerative diseaseRiluzole neuroprotection in a Parkinson's disease model involves suppression of reactive astrocytosis but not GLT-1 regulationConcordant signaling pathways produced by pesticide exposure in mice correspond to pathways identified in human Parkinson's diseaseAnimal models of Parkinson's disease: a source of novel treatments and clues to the cause of the disease.Pharmacological stimulation of metabotropic glutamate receptor type 4 in a rat model of Parkinson's disease and L-DOPA-induced dyskinesia: Comparison between a positive allosteric modulator and an orthosteric agonist.Allosteric modulation of the group III mGlu4 receptor provides functional neuroprotection in the 6-hydroxydopamine rat model of Parkinson's diseaseTherapeutic potential of targeting group III metabotropic glutamate receptors in the treatment of Parkinson's disease.Targeting glutamate receptors to tackle the pathogenesis, clinical symptoms and levodopa-induced dyskinesia associated with Parkinson's disease.Animal models of Parkinson's disease: a gateway to therapeutics?Therapeutic potential of targeting glutamate receptors in Parkinson's disease.The role of glutamate and its receptors in the proliferation, migration, differentiation and survival of neural progenitor cells.Group III metabotropic glutamate receptors: pharmacology, physiology and therapeutic potential.Molecular, Neurochemical, and Behavioral Hallmarks of Reserpine as a Model for Parkinson's Disease: New Perspectives to a Long-Standing Model.Regulation of neuronal communication by G protein-coupled receptors.Antiparkinsonian potential of targeting group III metabotropic glutamate receptor subtypes in the rodent substantia nigra pars reticulata.
P2860
Q26995351-06952547-0ABC-40F6-B16D-26FA1E34AE13Q34223052-147DA8BB-50E2-4D79-959B-661A8B5D831EQ34260081-54E85AEF-E977-4674-B4CC-4E763C39E054Q35589979-790C95F8-EE93-4921-B0CF-8E8D96AE0EE6Q35738538-1BD08B37-0A7E-4BF9-B24C-1E828E5BEEF1Q36252786-2AD5917B-6E2B-4979-B319-08C0DC8360F6Q37782115-8862874F-48F2-4154-8F41-31C9F682668CQ38056852-59FF82C2-A5F0-4205-9AD5-F9B2CDBE0763Q38155480-C27F6D37-614D-4747-945A-03C3F11A79A0Q38190016-A3CE110E-6124-462C-919C-AEE5B8D6D8C0Q38190420-C04869F0-372D-4D32-9B7E-79622AD38B49Q38242117-C57D3207-0BA9-49B6-99C5-A5CEDC5A8A8AQ38366271-FB2E0136-CC3B-4FA0-B0EE-541D902C7786Q38484504-AB5568F7-9159-419F-A1E1-194F4E92C3D6Q39265062-C10CA6D6-F3E8-4B1F-BD14-E1104C3BCA62
P2860
Symptomatic and neuroprotective effects following activation of nigral group III metabotropic glutamate receptors in rodent models of Parkinson's disease
description
2010 nî lūn-bûn
@nan
2010年の論文
@ja
2010年論文
@yue
2010年論文
@zh-hant
2010年論文
@zh-hk
2010年論文
@zh-mo
2010年論文
@zh-tw
2010年论文
@wuu
2010年论文
@zh
2010年论文
@zh-cn
name
Symptomatic and neuroprotectiv ...... models of Parkinson's disease
@en
Symptomatic and neuroprotectiv ...... models of Parkinson's disease.
@nl
type
label
Symptomatic and neuroprotectiv ...... models of Parkinson's disease
@en
Symptomatic and neuroprotectiv ...... models of Parkinson's disease.
@nl
prefLabel
Symptomatic and neuroprotectiv ...... models of Parkinson's disease
@en
Symptomatic and neuroprotectiv ...... models of Parkinson's disease.
@nl
P2093
P2860
P50
P1476
Symptomatic and neuroprotectiv ...... models of Parkinson's disease
@en
P2093
M Broadstock
M J O'Neill
S N Mitchell
P2860
P304
P356
10.1111/J.1476-5381.2010.00820.X
P407
P577
2010-08-01T00:00:00Z